Myriad Takes a Downgrade
On the heels of a CMS decision to reduce reimbursement for BRCA testing by roughly 50%, Myriad Genetics is getting a closer look from investors, and a downgrade from analysts.
Read MoreSearch Results for: genetic testing
Task Force Recommends Narrower BRCA Testing
Posted by Steve Halasey | Dec 31, 2013 | Breast, Molecular Diagnostics |
The US Preventive Services Task Force has issued a final recommendation on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women.
Read MoreCombiMatrix Gets Contract with FedMed Network
Posted by Steve Halasey | Dec 23, 2013 | Molecular Diagnostics |
Molecular diagnostics company CombiMatrix, Irvine, Calif, has entered into a contractual agreement for coverage of its diagnostic laboratory services with FedMed, a national provider network and healthcare financial services organization.
Read MoreNew York Approves Use of Prenatal Testing Portfolio by Natera
Posted by Steve Halasey | Dec 23, 2013 | Molecular Diagnostics, Prenatal Testing, Womens Health |
The New York State Department of Health has issued a clinical laboratory permit for Natera, of San Carlos, Calif, enabling the company to make its portfolio of preconception and prenatal tests available to expecting parents in New York State.
Read MoreHereditary Cancer Test Outperforms BCRA1/2 Genes
Posted by Jenny Lower | Dec 16, 2013 | Breast, Cancer, Molecular Diagnostics, Research |
In a recent clinical study, a hereditary cancer test from Myriad Genetics detected breast and ovarian cancer 51% more often than tests for BCRA1 or BCRA2 genes alone.
Read More